Skip to main content

Advertisement

Log in

Bumetanide Attenuates Cognitive Deficits and Brain Damage in Rats Subjected to Hypoxia–Ischemia at Two Time Points of the Early Postnatal Period

  • Research
  • Published:
Neurotoxicity Research Aims and scope Submit manuscript

Abstract

Neonatal hypoxia–ischemia (HI) is one of the main causes of tissue damage, cell death, and imbalance between neuronal excitation and inhibition and synaptic loss in newborns. GABA, the major inhibitory neurotransmitter of the central nervous system (CNS) in adults, is excitatory at the onset of neurodevelopment and its action depends on the chloride (Cl) cotransporters NKCC1 (imports Cl) and KCC2 (exports Cl) expression. Under basal conditions, the NKCC1/KCC2 ratio decreases over neurodevelopment. Thus, changes in this ratio caused by HI may be related to neurological disorders. The present study evaluated the effects of bumetanide (NKCC cotransporters inhibitor) on HI impairments in two neurodevelopmental periods. Male Wistar rat pups, 3 (PND3) and 11 (PND11) days old, were submitted to the Rice-Vannucci model. Animals were divided into 3 groups: SHAM, HI-SAL, and HI-BUM, considering each age. Bumetanide was administered intraperitoneally at 1, 24, 48, and 72 h after HI. NKCC1, KCC2, PSD-95, and synaptophysin proteins were analyzed after the last injection by western blot. Negative geotaxis, righting reflex, open field, object recognition test, and Morris water maze task were performed to assess neurological reflexes, locomotion, and memory function. Tissue atrophy and cell death were evaluated by histology. Bumetanide prevented neurodevelopmental delay, hyperactivity, and declarative and spatial memory deficits. Furthermore, bumetanide reversed HI-induced brain tissue damage, reduced neuronal death and controlled GABAergic tone, maintained the NKCC1/KCC2 ratio, and synaptogenesis close to normality. Thereby, bumetanide appears to play an important therapeutic role in the CNS, protecting the animals against HI damage and improving functional performance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

Availability of Data and Materials

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary material.

References

Download references

Funding

This study was supported by research grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Author information

Authors and Affiliations

Authors

Contributions

DNM and CAN contributed to the conception and design of the study; DNM, LEDC, FKO, AVSC, APRM, LMS, MMM, GPB, and CD contributed to the acquisition and analysis of data; DNM, CAN, and LEDC contributed to drafting the text.

Corresponding author

Correspondence to Diorlon Nunes Machado.

Ethics declarations

Ethical Approval

All procedures were performed in accordance with the international principles for the practice involving animals, listed in the Guide for the Care and Use of Laboratory Animals (8th edition, 2011) of the National Research Council of the National Academies, the normative of the National Council for the Control of Animal Experimentation and the Brazilian Society of Science in Laboratory Animals—Law nº 11.794, in Ethical approval was obtained by the review board of the Universidade Federal do Rio Grande do Sul protocol, under number #39344.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 269 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Machado, D.N., Durán-Carabali, L.E., Odorcyk, F.K. et al. Bumetanide Attenuates Cognitive Deficits and Brain Damage in Rats Subjected to Hypoxia–Ischemia at Two Time Points of the Early Postnatal Period. Neurotox Res 41, 526–545 (2023). https://doi.org/10.1007/s12640-023-00654-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12640-023-00654-3

Keywords

Navigation